Malignant triton tumor

Malignant triton tumor (MTT) is a rare form of cancer that is classified as a subtype of malignant peripheral nerve sheath tumor (MPNST). It is characterized by the presence of rhabdomyoblasts, which are immature cells that can develop into skeletal muscle cells. MTT is named after the triton salamander, in which similar tumors were first observed.

Epidemiology[edit]

MTT is extremely rare, accounting for less than 1% of all soft tissue sarcomas. It is most commonly diagnosed in young adults, with a median age of diagnosis of 30 years. There is a slight male predominance.

Pathogenesis[edit]

The exact cause of MTT is unknown. However, it is often associated with Neurofibromatosis type 1 (NF1), a genetic disorder that causes tumors to form on nerve tissue. Approximately half of all MTT cases occur in individuals with NF1.

Clinical Presentation[edit]

Patients with MTT often present with a rapidly growing mass. The most common locations for these tumors are the extremities and the trunk. Symptoms can vary depending on the location of the tumor, but may include pain, weakness, and loss of function in the affected area.

Diagnosis[edit]

Diagnosis of MTT is typically made through a combination of medical imaging studies and biopsy. Imaging studies such as MRI or CT scan can help to identify the location and size of the tumor, while biopsy can confirm the presence of rhabdomyoblasts, which are characteristic of MTT.

Treatment[edit]

Treatment for MTT typically involves a combination of surgery, radiation therapy, and chemotherapy. The goal of treatment is to remove or destroy the tumor and prevent the spread of cancer cells to other parts of the body.

Prognosis[edit]

The prognosis for MTT is generally poor, with a 5-year survival rate of less than 20%. Factors that can affect prognosis include the size and location of the tumor, the patient's age and overall health, and the extent to which the cancer has spread at the time of diagnosis.